Background. HLAMatchmaker is a recently developed computer-based algorithm to determine donorrecipient HLA compatibility at the molecular level. Originally designed for highly alloimmunized patients, this algorithm is based on the concept that immunogenic epitopes are represented by amino acid triplets on exposed parts of protein sequences of HLA-A, -B, and -C chains accessible to alloantibodies. Donor HLA compatibility is determined by intralocus and interlocus comparisons of triplets in polymorphic sequence positions. For most patients, HLAMatchmaker can identify certain mismatched HLA antigens that are zero-triplet mismatches to the patient's HLA phenotype and should, therefore, be considered fully histocompatible. The present study was designed to determine how class I HLA matching at the triplet level affects kidney transplant outcome.
Methods. We analyzed two multicenter databases of zero-HLA-DR-mismatched kidneys transplanted from 1987 to 1999. One database consisted of 31,879 primary allografts registered by U.S. transplant centers in the United Network for Organ Sharing database and the other consisted of 15,872 transplants in the Eurotransplant program.
Results. HLA-A,B mismatched kidneys that were compatible at the triplet level exhibited almost iden-tical graft survival rates as the zero-HLA-A,B antigen mismatches defined by conventional criteria. This beneficial effect of triplet matching was seen for both nonsensitized and sensitized patients and also for white and nonwhite patients.
Conclusions. These findings suggest that the application of HLAMatchmaker will increase the number of successful transplants, at least in the HLA-DR match combinations.
In kidney transplantation, the number of mismatched HLA-A, -B, and -DR antigens generally determines the degree of donor HLA compatibility. Many studies have shown that zero-HLA antigen-mismatched transplants have the highest success rates, and these findings have led to the allocation policy of mandatory sharing of zero-mismatched cadaver kidneys. Although only 9% of all cadaver kidney transplants in the United Network for Organ Sharing (UNOS) are zero-antigen mismatches (1), an organ allocation based on HLA matching is disadvantageous for racial minority groups who have different HLA antigen frequencies than the donor pool (2) (3) (4) (5) .
Another method for assessing donor-recipient compatibility considers public epitopes that are shared by HLA antigens belonging to so-called cross-reactive antigen groups (CREGs) (6 -8) . Such epitopes are largely determined by alloantibodies, and they have been defined for class I antigens encoded by the HLA-A and HLA-B loci. CREG matching considers the broader groups of HLA-A,B antigens with shared public epitopes rather than the specific HLA antigens. It provides an alternative HLA-based organ allocation system that would benefit more transplant candidates and provide more access to better-matched organs for minorities (9) .
Several studies have suggested CREG matching is associated with graft survival rates that are better or comparable to those allocated on HLA antigen matching (10 -18) , but others have not found a beneficial effect of CREG matching (19 -23) . The controversy about CREG matching is in part a result of the difficulty in defining the exact spectrum of public epitopes on all HLA antigens. The CREG matching system in UNOS uses 10 CREGs, but the actual number of public specificities seems to be considerably higher (6 -8,18,24) . Amino acid sequence information on HLA antigens has led to the identification of polymorphic residues that correspond to many public epitopes and private HLA antigens. Matching at the HLA residue level in retrospective analysis resulted in graft outcome similar to zero HLA-B, -DR-mismatched grafts (15, 25) , but a prospective analysis has not demonstrated a comparable benefit (26) .
This report deals with an alternative approach to determine donor-recipient HLA compatibility at the structural level. HLAMatchmaker is a computer algorithm that considers each HLA antigen as a string of polymorphic amino acid triplets in antibody-accessible positions of HLA molecules (27) (28) (29) . HLA compatibility is assessed at the structural level by determining the differences in triplet combinations between donor and recipient HLA molecules. HLAMatchmaker can identify HLA antigens that are mismatched by conventional criteria, but because they share all their triplets with the patient, they must be considered fully compatible at the epitope level. This program has been particularly useful in the identification of compatible donors for highly sensitized patients (30, 31) .
The present study was designed to determine how class I HLA matching defined by HLAMatchmaker affects kidney transplant outcome. The analysis was performed with the UNOS and the Eurotransplant databases of zero-HLA-DRmismatched transplants. We have found that HLA-A,B mismatching at the triplet level is associated with almost identical graft survival rates as the zero HLA-A,B antigen mismatches defined by conventional criteria.
MATERIALS AND METHODS
We analyzed two large cadaver kidney transplant databases. One consisted of 31,879 zero-DR-mismatched kidneys transplants in the United States from 1987 to 1999 and reported to the UNOS Scientific Registry. The second database comprised 15,872 zero-DR-mismatched kidney transplants in Austria, Belgium, Germany, Luxembourg, The Netherlands, and Slovenia from 1987 to 1999 and reported to the Eurotransplant Registry. Sensitized patients with a pretransplantation panel-reactive antibody (PRA) of more than 50% were considered separately from nonsensitized patients with a PRA less than 10%.
Serologic HLA-A and HLA-B typing information of recipients and donors was retrieved from the databases, and the HLA antigens were converted into strings of polymorphic triplets applying a previously described computer algorithm (29) . There are 113 polymorphic triplets distributed over 30 positions in HLA-A molecular sequence and 27 positions in the HLA-B molecular sequence. HLAMatchmaker assesses compatibility between donor and recipient by determining what triplets on donor HLA antigens are present or absent on any of the patient's own HLA antigens. A triplet in a given sequence position of a donor HLA antigen is considered a match if the recipient has this triplet in that position of any of its own HLA class I antigens. HLA compatibility is assessed by determining the total number of mismatched triplets on the HLA antigens of the donor. Certain HLA antigens are mismatched by conventional criteria but turn out to be fully compatible at the triplet level (29) . The Microsoft Excel version of the HLAMatchmaker program can be downloaded from the http://tpis.upmc.edu website.
This triplet-matching program was adapted to the UNOS and Eurotransplant databases, and standard Kaplan-Meier methods were applied to determine actuarial graft survival rates with death considered graft loss in the various match groups. Statistical significance was determined by log-rank comparisons of survival rates using two-sided P values.
RESULTS
This analysis was performed with two databases of zero-HLA-DR-mismatched transplants. The distribution of the HLA-A,B antigen mismatches was different between the UNOS and Eurotransplant databases; this might be related to differences in organ allocation policies in these programs. UNOS had a higher percentage of zero-HLA-A,B mismatches than Eurotransplant: 31.1% versus 21.6% (Table 1) ; this might be a result of the larger waiting list of patients in UNOS (32) . On the other hand, the higher percentages of one-and two-HLA-A,B antigen mismatches in Eurotransplant reflects a greater emphasis on minimizing the number of mismatched HLA antigens in the mismatches (24) . Overall, the average number of HLA-A,B mismatches was slightly higher for the UNOS transplants than the Eurotransplant cases (1.80 versus 1.65). The 5-year graft survival rates for zero-HLA-DR-mismatched transplants were 71.4% in recipients in the UNOS database and 76.8% in patients in the Eurotransplant database. Figure 1 shows the graft survival rates for zero-HLA-DRmismatched recipients, stratified by the number of HLA-A,B antigen mismatches. As expected, the zero mismatches had the highest success rates for both UNOS and Eurotransplant patients and graft survival decreased in a stepwise manner with increasing numbers of HLA-A,B antigen mismatches.
Analysis of the UNOS Data
The primary goal of this study was to compare the graft survival rates of the zero-HLA-A,B antigen mismatches with those HLA-A,B antigen mismatches that are compatible at the triplet level. Of the 21,270 zero-HLA-DR-mismatched cases with HLA-A,B antigen mismatches reported to the UNOS database, there were 183 cases that had zero-triplet mismatches. Graft survival rates were nearly identical between the patients with zero-triplet mismatches and those with zero-HLA-A,B,DR antigen mismatches. Recipients with one-triplet (nϭ32) and two-triplet mismatches (nϭ36) had similar survival rates, so we combined the zero-, one-, and two-triplet mismatches in a triplet match group (nϭ251). Figure 2 shows that this group had almost identical survival rates as the zero-HLA-A,B antigen mismatches. Recipients with 3-to 10-triplet mismatches and those with greater than 10-triplet mismatches had significantly lower graft survival rates (PϽ0.001).
The beneficial effect of matching at the triplet level was seen in both white and nonwhite recipients ( Table 2) . Twoyear graft survival rates are shown because the number (nϭ64) of nonwhite recipients (mainly African Americans) was too small for a longer follow-up interval. It should also be noted that the graft survival rates of the 3 to 10 and the greater than 10 triplet-mismatched groups were lower for nonwhite and white recipients.
The impact of triplet matching on sensitized and nonsensitized patients was also examined in the UNOS database analysis. Overall, sensitized patients with PRA greater than 50% (nϭ4,033) had poorer graft survival than unsensitized patients with PRA less than 10% (nϭ22,280). It is interesting to note that although the numbers are small, when stratified in this way, patients with zero-to two-triplet mismatches had graft survival rates similar to the zero-HLA-A,B antigen-mismatched transplants and strikingly higher than those with more than two-triplet mismatches (Table 3) . These data suggest that the beneficial effect of triplet matching applies equally to sensitized and nonsensitized transplant recipients. 
TABLE 1. Proportions of zero-HLA-DR-mismatched kidney transplants with different numbers of HLA-A,B antigen mismatches in the UNOS and Eurotransplant databases

TRANSPLANTATION
Analysis of the Eurotransplant Data
The Eurotransplant database had a somewhat different distribution of HLA-A,B antigen mismatches than the UNOS database. Although the proportion of zero-antigen mismatches was smaller (i.e., 21.6% vs. 31.1%), Eurotransplant had higher percentages of one-antigen mismatches (22.3% vs. 9.1%) and two-antigen mismatches (30.6% vs. 21.8%) than UNOS (Table 1) . Also, the numbers of cases with zero and few triplet mismatches were considerably higher and this permitted a more detailed analysis of the association of graft survival and the number of triplet mismatches. Table 4 compares the graft survival rates during a 5-year interval between the zero-HLA-A,B antigen mismatches (nϭ3426) and the HLA-A,B mismatches grouped according to the number of mismatched triplets. Overall, graft survival correlated significantly with the number of mismatched triplets (PϽ0.001). The zero-triplet mismatches (nϭ231) and the onetriplet mismatches (nϭ218) had almost the same graft survival rates as the zero-HLA-A,B antigen mismatches. For instance, the 5-year graft survival rate was 76.0% for the combined group of zero-and one-triplet mismatches (nϭ449) and 76.8% for the zero-HLA-A,B antigen mismatches. The two-triplet mismatch group had a lower graft survival rate than the zero-and one-triplet mismatches, but the difference was statistically not significant. Interestingly, the graft survival rates of the three-and four-triplet mismatch groups were similar to those of the zero-and one-triplet mismatches. Mismatching for five and more triplets was associated with significantly lower graft survival rates (PϽ0.001).
Altogether, these results demonstrate that matching at the triplet level is associated with excellent kidney transplant survival and that mismatching for up to two triplets has no significant adverse effect. The numbers of cases with high serum PRA values were too small for a meaningful analysis of a triplet matching effect on graft survival in sensitized patients. Also, insufficient numbers of cases were available in the Eurotransplant database to compare white and nonwhite recipients.
DISCUSSION
This analysis of two databases of zero-HLA-DR-mismatched kidney transplants provides evidence that HLA-A,B antigen mismatches with compatible amino acid triplets have similar graft survival rates to those with zero-HLA-A,B antigen mismatches. The practical implication of this finding is the possible use of the HLAMatchmaker algorithm to increase the number of well-matched transplants. Furthermore, triplet matching may benefit sensitized patients and nonwhite transplant candidates, for whom it is difficult to find donors with good matches.
In the UNOS database of zero-HLA-DR mismatches, the number of zero-to two-triplet mismatches represented only 251 (or about 1%) of the 21,270 HLA-A,B antigen-mismatched cases. In Eurotransplant, almost 7% of the 12,374 HLA-A,B antigen-mismatched cases had zero-to two-triplet mismatches. This finding indicates that the triplet matching algorithm will increase the availability of HLA-compatible donors. In an accompanying article, we address this issue and how the application of HLAMatchmaker will increase the probability of finding a suitable donor (33) .
Why do the zero-triplet and few-triplet mismatched transplants appear so successful? Designed originally for highly sensitized patients (27, 28) , the HLAMatchmaker algorithm considers only triplets that are in antibody-accessible positions of the HLA molecular structure. HLA-specific antibodies play a major role in graft rejection (34) , and matching at the humoral immune level (i.e., for epitopes recognized by such antibodies) can be expected to improve graft survival. HLA compatibility must also consider cellular immune mechanisms of graft rejection, such as class I HLA-specific cytotoxic T lymphocytes and indirect allorecognition of processed donor class I HLA antigens presented by recipient CD4 T cells. Although HLA matching at the cellular immune level must use different structural criteria (they are currently not defined), this humoral immunity-based matching strategy 27, 2003 permits the identification of triplet matches among the zero-HLA-DR mismatches that have the same high success rates as the conventional zero-HLA-A,B,DR mismatches.
We have also obtained evidence that kidney transplants mismatched for one or a few triplets may have equal graft survival rates as the zero-triplet mismatches. The Eurotransplant data seem to indicate excellent survival rates of kidney transplants with up to four mismatched triplets. These findings raise questions about the immunogenicity of triplets, and some of them may not play a determining role in matching. Indeed, a recent serologic analysis of sera from highly sensitized patients has identified several triplets with low immunogenicity in terms of specific antibody formation (29) .
In this study, the assignment of triplets to HLA antigens does lack precision because HLA typing was performed largely by serologic methods that cannot test for molecular subtypes. DNA-based typing will permit the definition of HLA subtypes and accurate assignments of polymorphic triplets.
The triplet polymorphism of HLA-C was not considered in this analysis because no reliable HLA-C typing information was available in the two databases. Many HLA-C antigens are in linkage disequilibrium with certain HLA-B antigens (35) . Therefore, a zero-HLA-B antigen mismatch is likely a zero-HLA-C antigen mismatch. On the other hand, a donor HLA-A,B phenotype with one or more mismatched antigens may more likely also have a HLA-C antigen incompatibility even if the mismatched HLA-A,B antigens are triplet matches. Fortunately, many incompatible HLA-C antigens are zero-triplet or a few-triplet mismatches (28) . The exception is HLA-Cw7, for which the polymorphic triplet repertoire is different than for the other HLA-C antigens. With currently available DNA typing methods for HLA-C typing and the application of the triplet-matching algorithm, it might become possible to fully assess the role of HLA-C matching in transplantation.
Many triplets seem to be equivalent to public epitopes expressed by CREGs of HLA antigens. For most patients, HLAMatchmaker can identify mismatched HLA antigens that are fully compatible at the triplet level. Many of them cross-react with HLA antigens of the patient, and this is in accordance with the CREG matching concept in kidney transplantation. CREG matching emphasizes the sharing of public epitopes between donor and recipient HLA antigens. Certain HLA antigens, however, carry private epitopes with considerable immunogenic potential and mismatching for them might be detrimental. This may explain why the beneficial effect of CREG matching on kidney transplant outcome remains controversial (10, 16, 17, 20, 21, 23) . HLAMatchmaker permits a fine tuning of the CREG matching algorithm because it considers the structural organization of public and private epitopes.
